Earlier, we did not have an objective standard tool to calculate risk/benefit scores most of the time, and such decisions were based on individual tumor clinicopathological features, grade, size, tumor stage, hormonal receptor status, and medical oncologist experience. This evidence concerns the gene NR4A1 and neoplasm.